Literature DB >> 23988434

Dihydropyrimidinase-like 3 regulates the inflammatory response of activated microglia.

J Manivannan1, S S W Tay, E-A Ling, S T Dheen.   

Abstract

Microglia, the resident immune cells of the CNS, are known to respond to injuries, infection and inflammation in the CNS by producing proinflammatory cytokines and phagocytosing cell debris and pathogens. In this study, we investigated the expression pattern and role of dihydropyrimidinase-like 3 (Dpysl3), a member of collapsin response mediator protein family, on the inflammatory reaction of microglia. Microarray analysis comparing the global gene expression profile of ameboid and ramified microglia has shown that Dpysl3 is mainly expressed in ameboid microglia in the 5-day postnatal rat brain. Immunohistochemical analysis revealed that Dpysl3 was intensely expressed in ameboid microglial cells in the rat brain till postnatal 7th day and then gradually diminished in ramified microglia of 2 weeks postnatal rat brain. Further, in vitro analysis confirmed that Dpysl3 expression was induced in activated BV-2 microglia treated with lipopolysaccharide (LPS). It is well documented that microglial activation by LPS increased the expression of inducible nitric oxide synthase (iNOS) and proinflammatory cytokines through the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity in BV-2 microglia. However, siRNA-mediated knockdown of Dpysl3 prevented the LPS-induced expression of iNOS and cytokines including interleukin-1 beta, and tumor necrosis factor-alpha as well as nuclear translocation of NF-κB in microglia. Remarkably, knockdown of Dpysl3 inhibited the migration of activated microglia coupled with deranged actin filament configuration (as revealed by F-actin cytoskeleton expression) in lamellipodia projecting from the cells. Knockdown of Dpysl3 also inhibited the phagocytic ability of activated microglia. These findings suggest that knockdown of Dpysl3 can inhibit activation, migration and phagocytic capability of microglia and consequently reduce neuroinflammation.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4′,6-diamidino-2-phenylindol; AMC; CNS; CRMPs; DAPI; Dpysl3; F-actin; IL-1β; LPS; NF-κB; NO; PBS; Phosphate-buffered saline; RMC; RT-PCR; Reverse Transcription–Polymerase Chain Reaction; TNF-α; ameboid microglial cells; central nervous system; collapsin response mediator proteins; dihydropyrimidinase like 3; filamentous actin; iNOS; inducible nitric oxide synthase; interleukin-1 beta; lipopolysaccharide; microglia; migration; nitric oxide; nuclear factor kappa-light-chain-enhancer of activated B cells; phagocytosis; proinflammatory cytokines; ramified microglial cells; siRNA; small interfering RNA; tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2013        PMID: 23988434     DOI: 10.1016/j.neuroscience.2013.08.023

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

1.  Anti-inflammatory effects of thymoquinone in activated BV-2 microglial cells.

Authors:  Equar Taka; Elizabeth A Mazzio; Carl B Goodman; Natalie Redmon; Hernan Flores-Rozas; Renee Reams; Selina Darling-Reed; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2015-06-27       Impact factor: 3.478

2.  Neuroprotective effect of grape seed extract on brain ischemia: a proteomic approach.

Authors:  Safwen Kadri; Mohamed El Ayed; Pascal Cosette; Thierry Jouenne; Salem Elkhaoui; Sami Zekri; Ferid Limam; Ezzedine Aouani; Meherzia Mokni
Journal:  Metab Brain Dis       Date:  2019-02-22       Impact factor: 3.584

Review 3.  CRMPs Function in Neurons and Glial Cells: Potential Therapeutic Targets for Neurodegenerative Diseases and CNS Injury.

Authors:  Jun Nagai; Rina Baba; Toshio Ohshima
Journal:  Mol Neurobiol       Date:  2016-06-23       Impact factor: 5.590

Review 4.  Collapsin Response Mediator Proteins: Novel Targets for Alzheimer's Disease.

Authors:  Tam T Quach; Aubin Moutal; Rajesh Khanna; Nicholas P Deems; Anne-Marie Duchemin; Ruth M Barrientos
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Crmp4 deletion promotes recovery from spinal cord injury by neuroprotection and limited scar formation.

Authors:  Jun Nagai; Yoshiteru Kitamura; Kazuki Owada; Naoya Yamashita; Kohtaro Takei; Yoshio Goshima; Toshio Ohshima
Journal:  Sci Rep       Date:  2015-02-05       Impact factor: 4.379

6.  Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer.

Authors:  Keiichi Yazawa; Fumio Nakamura; Daiki Masukawa; Sho Sato; Yukihiko Hiroshima; Yasuhiro Yabushita; Ryutaro Mori; Ryusei Matsuyama; Ikuma Kato; Hideki Taniguchi; Yoshio Goshima; Itaru Endo
Journal:  Transl Oncol       Date:  2020-02-24       Impact factor: 4.243

7.  Proteomic profiling of proteins in the dorsal horn of the spinal cord in dairy cows with chronic lameness.

Authors:  Daniel Herzberg; Pablo Strobel; Heine Müller; Constanza Meneses; Marianne Werner; Hedie Bustamante
Journal:  PLoS One       Date:  2020-01-28       Impact factor: 3.240

8.  Ruxolitinib attenuates secondary injury after traumatic spinal cord injury.

Authors:  Zhan-Yang Qian; Ren-Yi Kong; Sheng Zhang; Bin-Yu Wang; Jie Chang; Jiang Cao; Chao-Qin Wu; Zi-Yan Huang; Ao Duan; Hai-Jun Li; Lei Yang; Xiao-Jian Cao
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.